RecruitingPhase 2
A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder
Alkermes, Inc. · NCT07901179
View Study & Apply (opens in a new tab)
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–65 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 180
- US sites recruiting
- 1
- Study start
- October 2026
- Record last updated
- October 28, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this study is to assess the efficacy, safety and tolerability of ALKS 7290 following oral administration in adult participants with Major Depressive Disorder.
Being studied: ALKS 7290 Dose; Placebo
Conditions: Major Depressive Disorder (MDD)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Meets the DSM-5 criteria for MDD, as confirmed by both MINI and an adequate clinical psychiatric evaluation.
- Is otherwise healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring.
- Participants must be stable on permitted medication prior to screening.
- An inadequate response to an adequate dosage of antidepressant therapy in the current depressive episode.
- Symptoms of depression that are considered moderate to severe, based on assessments completed with the study team during both screening and baseline visits.
- Has a BMI within 18 to 35 kg/m2 at Screening
Exclusion Criteria
- Diagnosis of schizophrenia, schizoaffective disorder, or bipolar I or II disorder, moderate to severe substance use disorder
- Significant problems with memory, thinking, learning or understanding that could make it difficult to complete study activities or follow study instructions. This includes conditions such as dementia or other disorders affecting thinking and memory that have been present within the past two years.
- Participant poses a current suicide risk as assessed by the Investigator or as confirmed by the C-SSRS
- Any other psychiatric condition that could interfere with participation in the study.
Recruiting US locations
Alkermes Investigator Site
Jacksonville, FL 32256
Study contacts (from the official record)
- Director, Clinical Trial Manager · 888-235-8008 (US Only) · clinicaltrials@alkermes.com
- Director, Clinical Trial Manager · 571-599-2702 (Global) · clinicaltrials@alkermes.com
Similar studies in Florida
All sleep studies in Florida →- RecruitingPhase 2/Phase 3
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
Takeda
- Location
- Brandon, FL + 19 other US sites
- Eligibility basics
- Ages 18–71
- RecruitingPhase 3
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Axsome Therapeutics, Inc.
- Location
- Jacksonville, FL + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.
Incannex Healthcare Ltd
- Location
- Brandon, FL + 11 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
Pfizer
- Location
- Bradenton, FL + 2 other US sites
- Eligibility basics
- Ages 18+